Semaglutide reduced symptoms in patients with HFpEF and type 2 diabetes, improved physical capacity, and enhanced quality of life (as measured by KCCQ-CSS). It significantly reduced NT-proBNP and CRP levels. There was no evidence of an increase in adverse events, despite the intrinsic risk in patients with diabetes who present with comorbidities. The gene discussed is CRP; the disease is diabetes mellitus.